Based on network pharmacological analysis, 8 main bioactive compounds (palmatine, β-elemene, tetrandrine, fangchinoline, bifendate, calycosin, atractylenolide I, and hinesol) of FHD were predicted to have good affinity with 9 hub targets (CCL2, IL-10, PTGS2, TNF, MAPK1, IL-6, CXCL8, TP53, and VEGFA) for NS treatment. The gene discussed is IL6; the disease is hypoalphalipoproteinemia, primary, 1.